Patent ID: 9512481
Filing Date: 2016-12-06
CPC Classification: A61K,C12Q

Claim Text:
1. A method for treating a human patient with heart failure comprising treating the patient with an effective amount of a PDE3A inhibitor after the patient is determined to be homozygous for an insertion of an ectotropic viral integration site-1 (Evi-1) binding site in the phosphodiesterase type 3A (PDE3A) gene promoter, wherein the Evi-1 binding site insertion is 85% identical to SEQ ID NO:2 and is located within 2000 nucleotides 5′ of the PDE3A gene transcriptional initiation site and wherein the PDE3A inhibitor is amrinone, cilostazol, milrinone, quazinone, siguazodan, trequinsin, or enoximone.